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Abstract In this study, we analyzed the expression profile of
four genes (CCNA2, CCNB1, CCNB2, and CDK1) in laryn-
geal squamous cell carcinoma (LSCC) cell lines and tumor
samples.With the application ofmicroarray platform, we have
shown the overexpression of these genes in all analyzed
LSCC samples in comparison to non-cancer controls from
head and neck region. We have selected CDK1 for further
analysis, due to its leading role in cell cycle regulation. It is
a member of the Ser/Thr protein kinase family of proven on-
cogenic properties. The results obtained for CDK1 were fur-
ther confirmed with the application of reverse transcription
quantitative polymerase chain reaction (RT-qPCR) technique,
Western blot, and immunohistochemistry (IHC). The observed
upregulation of CDK1 in laryngeal squamous cell carcinoma
has encouraged us to analyze for genetic mechanisms that can
be responsible this phenomenon. Therefore, with the
application of array-CGH, sequencing analysis and two
methods for epigenetic regulation analysis (DNA methylation
and miRNA expression), we tried to identify such potential
mechanisms. Our attempts to identify the molecular
mechanisms responsible for observed changes failed as we
did not observe significant alterations neither in the DNA
sequence nor in the gene copy number that could underline
CDK1 upregulation. Similarly, the pyrosequencing and
miRNA expression analyses did not reveal any differences in
methylation level and miRNA expression, respectively; thus,
these mechanisms probably do not contribute to elevation of
CDK1 expression in LSCC. However, our results suggest that
alteration ofCDK1 expression on bothmRNAand protein level
probably appears on the very early step of carcinogenesis.
Keywords CDK1 . Overexpression . Genemethylation .
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Introduction
Larynx squamous cell carcinoma (LSCC) is one of the most
frequent types of head and neck cancer [1]. The main etiolog-
ical causes of this type of cancer are well known and include the
synergistic effects of tobacco smoking and alcohol abuse [2].
Chromosomal aberrations resulting in alterations in gene
expression (downregulation of tumor suppressor genes or
overexpression of oncogenes) are one of the genetic factors
contributing to the development of this cancer. Until now,
several oncogenes have been shown to be involved in the
development of head and neck cancers including CCND1,
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FGF3, FGF4, CTTN [3], or EGFR [4]. In our previous work,
we have shown also other oncogenes like the ORAOV1,
FADD [5], and CRKL [6] as potentially related to LSCC.
As aberrant cell cycle control plays a significant role in tumor
development, we focused on the genes involved in this proces.
We analyzed the expression level of group of four genes (CDK1,
CCNB1, CCNB2, and CCNA2) engaged in cell cycle control.
CDK1 (cyclin-dependent kinase 1) gene is an important factor
of the cell cycle control system [7, 8]. Together with cyclin B
(CCNB1 and CCNB2), it forms an active MPF (maturation-
promoting factor) which makes cell enter mitosis [9]. The A
cyclin (CCNA2) binds CDK1 during the transition from G2 to
M phase [10]. Moreover, CDK1 is required for mammalian cell
proliferation as it is the only CDK that can initiate the onset of
mitosis [11]. For all these genes, we observed gene upregulation
in LSCC cell lines and tumor samples as compared to non-
cancer controls. However, due to the leading role of CDK1 in
cell cycle control and regulation, we have chosen the CDK1 for
further analysis. This gene is a member of the Ser/Thr protein
kinases family. The oncogenic potential of these enzymes was
demonstrated [12–14]. The CDK1 protein is a catalytic subunit
of M-phase promoting factor essential for the G1/S and
G2/M transition in eukaryotic cell cycle.
Interesingly, in model organism Saccharomyces cerevisiae,
the 75 target genes of Cdk1 were shown to control cell cycle,
DNA replication and segregation, transcriptional programs,
and cell morphogenesis [15]. These findings suggest that de-
regulation in CDK1 gene may play a significant role in
cancerogenesis. Moreover, the involvement of CDK1 in
tumorgenesis was postulated in various types of cancer, in-
cluding laryngeal cancer [16, 17].
Due to the suggested role of CDK1 in tumorigenesis, we
analyze here the CDK1 DNA copy number, gene sequence,
DNA methylation status, and miRNA expression profile with
the aim to identify the responsible mechanism for the ob-
served CDK1 upregulation in LSCC.
Materials and methods
Cell lines
Twenty-five cell lines derived from laryngeal cancer were
used. The cell line characteristics are shown in Table 1.
Primary tumor samples
Primary tumor samples used for the mRNA
and microRNA expression analysis and pyrosequencing
Forty-five laryngeal cancer samples (1 female and 44 males)
were used in the study. The average patients age was 61 years
(ranged 42–84). The TNM and G status details are shown in
Table S1. During the surgery, each sample was divided into
three parts and designated for histopathological analysis,
DNA isolation (immediate freezing in −80 °C), and RNA
analysis (storage in RNAlater, Sigma, according to man-
ufacturer’s instruction). Only samples containing more
than 60 % of tumor cells were chosen for the study.
The study was approved by the local ethical board of
Medical University in Poznan.Written consent was obtained
from all donors.
Primary tumor samples used for immunohistochemistry
The studies were performed on a group of 40 patients (5 fe-
males, age, 50–69 and 35 males, age, 44–77), who underwent
total laryngectomy. Based on histopathological examination,
performed by two independent pathologists, in all cases, laryn-
geal squamous cell carcinoma (LSCC) was diagnosed. The tu-
mor stage was determined according to the current TNM clas-
sification published by the International Union Against Cancer
(IUAC). The TNM and G status details are shown in Table S1.
The immunohistochemical studies were performed on se-
lected archival formalin-fixed paraffin embedded (FFPE) tis-
sue sections. All cases were revised and selected by two inde-
pendent pathologists according to hematoxylin and eosin-
stained tissue sections. In each sample, cancer cells occupied
approximately 80 % of tissue area.
Control samples
Control samples used for the expression analysis
Various types of non-malignant samples were used as controls
for microarray and reverse transcription quantitative polymer-
ase chain reaction (RT-qPCR) expression analysis: the
commercially available human total RNA derived from
healthy larynx (Total Larynx RNA, Stratagene, Agilent
Technologies, Waldbronn, Germany), the RNA derived from
bronchial airway epithelia reconstituted in vitro (two donors)
(EC, Epithelix Sarl, Geneve, Switzerland), normal mucosa
derived from surgical margin during laryngectomy (LX10),
normal human bronchial/tracheal epithelial cells—NHBE
(Lonza, Verviers, Belgium), and human tracheal epithelial
cells—HTEC (PromoCell, Heidelberg, Germany).
Control samples used for CDK1 gene promoter DNA
methylation analysis
Two groups of controls included 20 DNA samples isolated
from head and neck region. Ten were derived from the oral
cavity epithelium (buccal swabs, W1–W10) from healthy do-
nors. The second group of controls (K1–K10) were collected
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during surgeries not associated with cancer and include sam-
ples from the resected epithelium of Reinke’s edema and nor-
mal vocal fold fragments removed during surgical widening
of the glottis in patients with bilateral vocal cord paralysis.
Additionally, the fully methylated standard (MK, Millipore,
Hilden, Germany) and unmethylated DNA (UM), i.e., the
whole genome amplified DNA from peripheral blood lym-
phocytes (prepared with GenomePlex® Whole Genome
Amplification Kit) were used in each run.
Protein lysates used for Western blot analysis
The presence of the examined protein (CDK1) was analyzed in
comparison to commercially available total larynx tissue lysates
(Larynx Human Tissue Lysates from adult normal tissue—
ab44731 and ab44733, pooled, Abcam,UK), four protein lysates
obtained from the non-cancer tissue samples (K12-K15), and
three lysates from the epithelial cells (primary culture obtained
in our laboratory) derived from the non-cancer tissue samples
(K2, K3, K6). As positive controls, the Jurkat cell line lysate
(Jurkat E6.1, Human T-cell lymphocytes, ECACC, Salisbury,
UK) or HeLa lysate (cervical cancer cell line) was used.
Control samples used for the immunohistochemical
analysis of CDK1 protein
The control material for the immunohistochemical studies
consisted of archival FFPE tissue sections, revised, and select-
ed by two independent pathologists. The sections contained a
disease-free normal mucosa, at least 2 cm distant from the
tumor margins. To establish the immunohistochemical proto-
col, a series of positive and negative control reactions were
performed. The positive control reaction was performed on
placenta, where the presence of CDK1 protein expression
was indicated (reference sources: [18]; the Human Protein
Atlas; and manufacturer antibodies datasheet). The negative
Table 1 Cell line characteristics
Cell line number Sex Age
(years)
Primary tumor location TNM Specimen site Type of
lesion
Grade Survival
UT-SCC-6A F 51 Supraglottic larynx T2N1M0 Larynx rec G1 DWD 31 months
UT-SCC-6B F 51 Supraglottic larynx T2N1M0 Neck met G1 DWD 31 months
UT-SCC-8 M 42 Supraglottic larynx T2N0M0 Larynx pri G1 DWD 35 months
UT-SCC-11 M 58 Glottic larynx T1N0M0 Larynx rec G2 DNE >5 years
UT-SCC-13 M 53 Supraglottic larynx T3N0M0 Larynx rec G2 DWD 11 months
UT-SCC-19A M 44 Glottic larynx T4N0M0 Larynx pri G2 DNE >5 years
UT-SCC-19B M 44 Glottic larynx T4N0M0 Larynx pri (per) G2 DNE >5 years
UT-SCC-22 M 79 Glottic larynx T1N0M0 Larynx rec G2 DWD 28 months
UT-SCC-23 M 66 SCC transglottic T3N0M0 Larynx pri (per) G1 DNE >5 years
UT-SCC-29 M 82 Glottic larynx T2N0M0 Larynx pri G1 DNE 10 years and 4 months
UT-SCC-34 M 63 Supraglottic larynx T4N0M0 Supraglottic larynx pri G1 DWD 10 months
UT-SCC-35 M 50 Glottic larynx T2N0M0 Larynx resid G2 DWD 10 months
UT-SCC-38 M 66 Glottic larynx T2N0M0 Larynx pri G2 DWD 16 months
UT-SCC-42B M 43 Supraglottic larynx T4N3M0 Neck pri G3 DWD 2 months
UT-SCC-49 M 76 Glottic larynx T2N0M0 Larynx pri G2 DWD 2 years and 7 months
UT-SCC-50 M 70 Glottic larynx T2N0;rT2N0 Larynx rec G3 ANE >5 years
UT-SCC-57 M 76 Glottic larynx T2N0M0 Larynx rec G1-G2 DWD 4 years
UT-SCC-75 M 56 SCC laryngis T2N2BM0 Larynx pri G2 D, NED 2 years and 6 months
UT-SCC-106A M 59 SCC plicae vocalis T1AN0M0 Larynx pri G2 DNE second pri 4 years and
1 month
UT-SCC-106B M 59 SCC plicae vocalis rT3N0M0 Larynx rec G3 DWD 5 days
UT-SCC-107 M 46 SCC laryngis supraglottis T4N2CM0 larynx pri G2 DNE 19 months
UT-SCC-108 M 68 SCC laryngis supraglottis T2N0M0 larynx pri G3 DWD 19 months
UT-SCC-113 M 50 SCC laryngis transglottica T3N0M0 larynx pri G3 DWD 17 months
UT-SCC-116 M 60 SCC laryngis supraglottis T4N1M0 larynx pri G2 DWD 9 months
UT-SCC-117 M 71 SCC laryngis (resid T2N0M0) T2N0M0 Larynx rec G2 DWD 47 months
All cell lines were obtained in University of Turku (Finland)
M male, F female, TNM TNM classification (T tumor, N lymph node involvement, M distance metastases), pri primary tumor, rec recurrence, met
metastasis, per persistent tumor, DWD died with the disease, DNE died with no disease evident, ANE alive with no disease evident
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control reaction was performed by substituting the primary
antibody by the 1 % BSA (bovine serum albumine) solution
in PBS (phosphate buffered saline).
For all the control samples used in our study, an appropriate
agreement from the bioethical board of the Poznan Medical
University was obtained.
Cell culture
The culture condition for cell lines and primary cultures of
epithelial cells were described elsewhere with minor modifi-
cation [5, 19, 20]. For DNA, RNA, and protein isolation, cell
lines were cultured to 80 % confluence and then harvested
with 0.1 % trypsin and 0.2 % EDTA. The cell lines used as
controls for Western blot were cultured under identical condi-
tions, using the modified Eagle medium (MEM) for HeLa and
RPMI-1640 medium for the Jurkat cell line, with 100 U/mL
penicillin/streptomycin medium, 37 °C, 5 % CO2).
DNA, RNA, and protein isolation
Nucleic acids from cell lines, tumor samples, and peripheral
blood lymphocytes were isolated according to standard
methods: phenol/chloroform extraction and ethanol precipita-
tion for DNA and Chomczynski’s method with application of
Trisol for RNA [21]. Nucleid acids purity and concentration
was analyzed as described elsewhere [22].
Total protein extraction from the LSCC cell lines and con-
trols (except tissue samples) was performed with
Nonidet-P40 (NP-40) buffer with the Protease Inhibitor
Cocktail (LabEmpire, Rzeszow, Poland). Total protein lysates
from the non-cancer tissue samples were obtained with the use
of FASTPREP-24™ 5G Instrument (MP Biomedicals) after
the grinding in liquid nitrogen Protein concentration was mea-
sured with standard Bradford method [23].
Microarray-based gene expression analysis
Expression analysis was performed on GeneChip Human
Genome U133 Plus 2.0 Array (Affymetrix) for 10 cell lines
(UT-SCC-6A, −11, −19B, −22, −29, −34, −57, −106A, −107,
−116), 5 tumor samples (out of 45 collected), and 3 control
samples (Total Larynx RNA, EC, LX10). The microarrays
were performed and analyzed as described elsewhere [5, 24,
25]. The number of tags used to analyze the expression of
chosen genes was as follows: two tags for the CCNA2 gene
(203418_at and 213226_at), one for CCNB1 (214710_s_at),
and one for CCNB2 (202705_at). Two tags were used to an-
alyze CDK1 expression: 203213_at and 203214_x_at as they
correspond to entire coding exons of the gene. The gene up-
regulation was defined as increased gene expression observed
for analyzed tag in comparison to expression level of this tag
in at least two of the three non-cancer controls.
Reverse transcription and quantitative real-time PCR
Total RNA from 25 LSCC cell lines and 3 non-tumor control
samples (Total Larynx RNA, NHBE cells and HTEC cells)
were used to synthesize the cDNA template using of
Enhanced Avian RT First Strand Synthesis Kit (Sigma-
Aldrich), according to manufacturer’s protocol. RT-qPCR
primers were designed with the use of Beacon Designer™
7.5 (PRIMER Biosoft International) and the specificity was
verified with the primer BLAST software (http://blast.ncbi.
nlm.nih.gov/Blast.cgi). Three genes were used as reference
genes: ARNT, UBC, and GAPDH. The primer sequences are
listed in Table S2. Quantitative real-time PCR was performed
with the iCycler iQ5 (Bio-Rad), and the gene expression pro-
file was analyzed with a detection system using iQ5 Optical
System Software 2.0 (Bio-Rad Laboratories). The annealing
temperature applied forCDK1 and reference genes was 55 °C;
detailed PCR conditions are presented in Supplementary data.
For PCR, the 5×HOT FIREPol® EvaGreen® qPCRSupermix
(Solis BioDyne, Estonia) according to the manufacturer’s
protocol was used. For each sample, 0.4 μL of cDNA
was used (undiluted reverse transcription product de-
rived from 8 μg RNA in 40 μl reaction). The melting
curve, determination of PCR efficiency, PCR data anal-
ysis, and statistics were previously described [6]. To
estimate the changes in gene expression, the cutoff
point value was calculated according to the scheme: three-
times standard deviation of the controls plus the expression
value of the highest control.
CDK1 protein western blot analysis
The whole cell lysates from 25 cell lines and 8 samples from
the non-cancer larynx tissue were used. In each blot, positive
control (Jurkat and/or HeLa cell line lysate) was used.
Detailed information can be found in the Supplementary data.
The rabbit polyclonal anti-CDK1-C-terminal antibody
(ab7953, Abcam, UK, dilution 1:1000) was applied for all
25 cell lines and 8 non-cancer larynx tissue lysates. The sec-
ond, N-terminal antibody (ab131011, Abcam, UK, dilution
1:6000) was used for the analysis of 7 LSCC cell lines (of
the 25 collected) and total larynx tissue lysate. Furthermore,
the anti-CDK1 (phospho T161) antibody (ab138389, Abcam,
UK, dilution 1:750) was applied for 24 LSCC cell lines. Blots
were incubated overnight in 4 °C and secondary antibody
(goat anti-Rabbit, ab 97051, Abcam, UK, 1:38500) was
applied (2 h, room temperature). Rabbit anti-GAPDH
(ab 9485, Abcam, UK, dilution 1:2500) antibody was
used as a loading control. For the protein detection,
SuperSignal West Pico Chemiluminescent Substrate
(Thermo Scietific, Rockford, IL USA) was used and
the images were scanned and analyzed with the ChemiDoc
XRS+ System (BioRad).
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Immunohistochemical analysis of laryngeal cancer
formalin-fixed paraffin embedded tissue sections
The level of CDK1 protein expression was performed using
automated morphometric methods in ImageJ 1.46a Program,
using authors’macro described earlier [26]. The representative
microphotographs were taken at ×20 original objective mag-
nification in the light microscope ECLIPSE E800 (Nikon
Instruments Europe, Amsterdam, Netherlands), with Nikon
Digital Sight DS-5Mc camera (Nikon Instruments Europe,
Germany) driven by 4NIS Elements F 3.0 software (Nikon
Instruments Europe, Germany). First, taken microphotographs
were converted using BColour Deconvolution^ option, where
the brown pigment was Bisolated^ from microphotography.
Subsequently, using the BThreshold^ option, the microphotog-
raphy was converted into an 8-bit version, which allowed to
creation of so-calledmask. The created Bmask^was applied on
the original microphotography, and conversions of the color
intensity into numerical data were performed. The level of
CDK1 protein expression was evaluated according tomodified
immunoreactive scale (IRS) described first by Remmele and
Stegner [27] and used (partially in modified version) in our
previous publications [28–30]. The IRS was evaluated as the
ratio of the percentage of positive stained cells/area (PP) and
the intensity of the color reaction (SI) (IRS=SI×PP).
Microarray DNA copy number analysis (array-CGH)
Array-CGH profiles from 13 cell lines from our previous
study were used [5, 24, 25].
The log2ratio for the DNA region: chr10:62,208,242-62,
223,930 covering the CDK1 gene (according to NCBI36/
hg18) Assembly) was analyzed. The mean log2 ratio of tags
for the DNA region containing the CDK1 gene was calculat-
ed. The mean log2ratio value between 0.5 and −0.5 was as-
sumed as normal.
The analysis of CDK1 gene promoter DNA methylation
by bisulfate pyrosequencing
DNA samples from 25 cell lines, 41 tumor samples, and con-
trols (oral epithelium—buccal swabs, normal head, and neck
tissue samples) were used. PurifiedDNAswere convertedwith
bisulfite solution with the use of EpiTect DNA Modification
Kit (QIAGEN, Germany), according to the manufacturer’s
protocol. The primer designing and pyrosequencing protocol
was performed as described elsewhere [22]. Fully methylated
and unmethylated controls were used in each run. Seven
CpG sequences in one CpG island were analyzed. See
Supplementary data for PCR details and cutoff points calcu-
lationmethod. Samples with DNAmethylation level above the
established upper cutoff point and below the lower cutoff point
were regarded as hyper- and hypomethylated, respectively.
Sequencing analysis
Primer pairs for mutation analysis of coding exons and intron–
exon junctions of CDK1 gene were designed with the use of
Primer3 v.0.4.0 online tool (http://bioinfo.ut.ee/primer3-0.4.0/).
Primer details are listed in Table S3. Detailed PCR conditions are
available in Supplementary data. PCR products were sequenced
using Big Dye Terminator Sequencing Kit Cycle v3.1 (Applied
Biosystems, Inc. (ABI), Foster City, CA, USA), according to the
manufacturer’s protocol and separated using ABI PRISM 310
Genetic Analyzer (Applied Biosystems). The results were
analyzed using Sequencing Analysis v. 5.2-5.4 software’s and
the CodonCode Aligner software (demo mode). The reference
sequence for CDK1 gene was obtained from RefSeq database;
NM_001786; UCSC Genome Browser GRCh37/hg19.
Microarray-based microRNA expression analysis
MicroRNA expression analysis was performed using the
Agilent Human microRNA Expression Microarray 66K
(based on miRBase 16.0 and updates) on 16 LSCC cell lines,
5 representative primary LSCC tumor samples (out of 45 col-
lected), and 3 non-tumor controls (Total Larynx RNA, NHBE
cells and HTEC cells). To delineate the microRNAs with the
highest probability to regulate CDK1 gene, we used the fol-
lowing selection criteria: (1) significantly up or downregulat-
ed miRNAs, with at least twofold change as compared to
controls, delineated by miRNA expression microarrays, (2)
miRNAs predicted in silico to target CDK1 by at least three
miRNA databases, using MiRWalk tool (from http://www.
umm.uni-heidelberg.de/apps/zmf/mirwalk/index.html) and
showing at least eight seed nucleotide homology (p<0.05).
Results
Microarray-based gene expression analysis
For all chosen genes, the expression level was higher in both
cell lines and tumor samples as compared to non-cancer con-
trols. For analyzed cyclins, the gene upregulation was shown
in 9/10 (90%) LSCC cell lines and 5/5 (100%) tumor samples
(data not shown). Among them, we choose CDK1 for further
analysis, due to its leading role in cell cycle regulation and
proven oncogenic potential of this group of enzymes. For the
CDK1 gene, the analyzed tags (203213_at and 203214_x_)
indicated higher expression of the CDK1 gene in all analyzed
cell lines, tumor samples, and controls. The expression level
was higher both in cell lines and in tumor samples as com-
pared to non-cancer controls (p<0.05; Mann-Whitney U test,
Fig. 1). No statistically significant difference between cell
lines derived from primary and recurrence tumors was ob-
served, but the CDK1 gene expression level was higher in
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primary tumor cell lines as compared to controls (p<0.05, U
test for both tags, Fig. 1). Thus, significantly higher expres-
sion level was observed in tumor samples and cell lines com-
pared to non-cancer controls.
Quantitative real-time PCR
To confirm the overexpression of the CDK1 gene, the quanti-
tative real-time PCR technique was performed on LSCC cell
lines and non-cancer controls from head and neck region.
Higher expression levels of the CDK1 gene has been demon-
strated in 9/25 (36 %) cell lines as compared to three non-
cancer controls (p<0.05; Mann-Whitney U test, Fig. 2).
Statistically significant difference between expression in
LSCC cell lines in comparison to controls was observed, but
there is no significant difference between cell lines derived
from primary tumors and recurrent tumors (Fig. 2). The results
confirmed our initial observation of the CDK1 gene overex-
pression in LSCC. No correlation of CDK1 gene expression
level with tumor phenotype (TMN and grade status) or pa-
tients survival was observed.
Western blot analysis results
To determine the expression of CDK1 on protein level,
Western blot analysis was performed. As was shown with
the C-terminal anti-CDK1 antibody, the CDK1 protein was
present in all 25 analyzed cell lines. Trace amount of CDK1
protein was detected in five of the non-cancer larynx tissue
samples (i.e., K6, K12, K13, and K14 and total larynx tissue
lysate.) The N-terminal anti-CDK1 antibody has shown the
presence of CDK1 protein in all seven LSCC cell line lysates
but absent in the total larynx lysate. The analysis of 24 LSCC
cell lines with the application of anti-CDK1 (phospho T161)
antibody has demonstrated the presence of phosphorylated
CDK1 protein in 22 LSCC cell lines; in 1 LSCC cell line
(UT-SCC-49) trace amount of analyzed protein was observed;
and in one LSCC cell line (UT-SCC-57), lack of phosphory-
lated CDK1 protein was shown. The positive control lysates
has demonstrated the presence of CDK1 protein, and the load-
ing control—GAPDH protein was present in all analyzed tis-
sue lysates. For all the analyzed proteins, one band with ade-
quate size was observed (Fig. 3).
Fig. 1 TheCDK1 gene expression analysis (microarray). Box plots show
gene expression level in cell lines derived from primary tumors, recurrent
tumors, and tumor samples in reference to non-cancer controls from head
and neck region. Figure presents results obtained for two most represen-
tative tags: 203213_at (left) and 203214_x_at (right). The Mann–
Whitney U test was performed
Fig. 2 The box plot of RT-qPCR
results showing CDK1 gene ex-
pression levels in cell lines de-
rived from laryngeal cancer re-
currence tumors, primary tumors,
and controls. The Mann–Whitney
U test was performed. UT-SCC-
6B cell line was excluded from
this part of analysis as it is derived
from metastasis tumor
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This analysis has shown the presence of the CDK1 protein
in LSCC and its absence or small amounts in controls derived
from non-cancer tissue from the larynx or regions surrounding
the larynx. As was shown, in LSCC, the CDK1 is present in
active-phosphorylated form. Moreover, this analysis shown
the lack of the changes in protein length resulting from the
CDK1 gene polymorphism rs3212319.
IHC analysis results
The immunohistochemical studies were performed to evaluate
the localization of CDK1 protein expression in LSCC primary
tumors, as well as for description of the differences in protein
expression (cytoplasmic vs. nuclear) in research LSCC group
of patients. The analyses showed nuclear-cytoplasmic expres-
sion of CDK1 protein in all 40/40 (100%) primary LSCC and
in all 18/18 (100 %) cases of normal mucosa (Fig. 4a), but
higher CDK1 expression in LSCC tumors median [CDK1
IRS=111.00] compared to normal mucosa median [CDK1
IRS=108.00] was observed. In 20/40 LSCC cases, we have
revealed the nuclear expression of CDK1 protein; the remain-
ing 20/40 cases revealed only cytoplasmic expression of ana-
lyzed antigen. No significant differences in expression of the
studied protein was observed between primary LSCC and
control group (p=0.962938) (Fig. 4b,c).
According to lymph node involvement, we have revealed
lower CDK1 protein expression in patients without lymph
node metastases (CDK1IRS N (0)=107) compared to the pa-
tients with lymph node involvement (CDK1IRS N (+)=115)
(Fig.4b,c). Moreover, in LSCC N (0) group, 9/20 cases re-
vealed nuclear expression of CDK1, and in LSCC N (+)
group, 11/20 cases revealed the nuclear expression of
established antigen. No significant differences in expression
of the studied protein was observed in the analyzed groups
(p=0.821868). Whereas, no significant differences between
nuclear and cytoplasmic expression, as well as lack of corre-
lation between nuclear-cytoplasmic ratio of CDK1 expression
according lymph node metastases was shown. The differenti-
ated pattern of CDK1 expression profile may indicate the
heterogeneity of the LSCC.
Microarray-based DNA copy number analysis
We first analyzed available array-CGH profiles to check for
possible copy number gains of the CDK1 locus in the 13
LSCC cell lines. In all instances, the mean log2 ratio for ana-
lyzed LSCC cell lines ranged from −0.20 to 0.15. Therefore,
in all 13 cell lines, DNA copy number changes in the CDK1
locus cannot account for the observed evaluated expression
level of the CDK1 gene in LSCC.
CDK1 gene sequencing results
As no copy number alterations, that could explain elevated
expression of CDK1, were identified, we screened for poten-
tial activating mutations in coding sequences of the gene. Two
common SNP variants were found in the analyzed samples:
rs3212319 (15/25 cell lines) and rs1871446 (24/25 cell lines).
Fig. 3 Western blot results obtained for different types of anti-CDK1
antibodies. The anti-CDK1 C-terminal antibody (upper panel) was ap-
plied for analysis of LSCC cell lines (left) and non-cancer head and neck
tissue (right) lysates, the anti-CDK1 (phospho T161) antibody (lower
panel, left) and the N-terminal anti-CDK1 antibody (lower panel, right)
were applied on the LSCC cell line lysates. The numbers used are the
LSCC numbers; K2, K3, K6, K12–K15 tissue sample donors numbers, L
total larynx tissue lysate, J Jurkat cell line lysate, H HeLa cell line lysate.
GAPDH was used as a loading control and Jurkat and HeLa cell lines
were the positive controls. The samples where the trace amounts of
CDK1 protein were observed are underlined
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The rs3212319 polymorphism is an intronic variant
(NC_000010.10: g.62551816delC; NM_001786.4: c.653+
5delC; (GRCh37/hg19)) and results in a deletion of the cyto-
sine in the position +5 in intron 6. Of the 15 affected samples,
13 were heterozygotes (C/-) and 2 were deleted in a homozy-
gous manner (−/−). The rs1871446 polymorphism is a 3′UTR
variant and results in a A>G substitution (NC_000010.10:
g.62553763A > G; NM_001786.4: c.*30A >G; UCSC
(GRCh37/hg19). Of the 24 affected samples, 4 were hetero-
zygous alterations (A/G), while the rest were homozygotes
(G/G). No other alterations in coding sequence or exon-
intron junction site were detected. Therefore, regarding the
expression data, most probably none of these SNP is associ-
ated with the elevated CDK1 observed in LSCC.
DNA methylation analysis of CDK1 promoter region
by pyrosequencing
The changes in pattern of DNA methylation is one of the
mechanisms of the gene transcription regulation. DNA meth-
ylation level of CDK1 gene promoter was analyzed in all cell
lines and primary tumor samples. The buccal swabs and non-
cancer head and neck tissue samples were used as controls.
The normal DNA methylation level was estimated to range
between 1.59 and 13.7 %. The mean methylation for the
LSCC cell lines ranged between 3.33 and 6.81 % and for the
tumor samples ranged 0 %–1.46 %. Therefore, no meaningful
differences were found between the samples. Thus, the CDK1
gene hypomethylation was excluded as a mechanism of the
gene upregulation.
Microarray-based microRNA expression analysis
Lastly, we analyzed another epigenetic mechanism that on
account for changes in gene expression—miRNAs. We delin-
eated the group of microRNAs with significant downregulat-
ed expression between 16 cell lines, 5 primary tumor samples,
and 3 controls. The analysis has revealed 12 downregulated
miRNA genes. None of this was reported to be involved in
CDK1 gene regulation. Therefore, we failed to delineate any
miRNA which could regulate CDK1 expression level in the
analyzed cases.
Discussion
In the current study, we have analyzed the expression pattern
of group of genes—CCNB1, CCNB2, CCNA2, and CDK1 in
laryngeal squamous cell carcinoma. All of the chosen genes
are important factors in eukaryotic cell cycle. We have shown
that all the analyzed genes are upregulated in LSCC cell lines
and tumor samples as compared to non-cancer head and neck
controls. From this group of genes, we have chosen the CDK1
gene for further analysis in context of searching the new po-
tential oncogenes in LSCC. The main criterion we assumed
for choosing this gene was its role in cell cycle control. CDK1
is a member of the Ser/Thr protein kinase family, and its prod-
uct is a catalytic subunit of M-phase promoting factor, essen-
tial for G1/S and G2/M phase transitions of eukaryotic cell
cycle. The oncogenic character of Ser/Thr protein kinases like
B-Raf and PIM1was shown [12–14]. It was demonstrated that
Fig. 4 Immunohistochemical representative microphotographs
representing the cdk-1 expression in normal mucosa (represented as co-
lumnar epithelium); on the following three micrographs, there are pre-
sented fragments of mucosa covered with squamous cell epithelium with
low and average dysplasia, then primary LSCC in patients without lymph
node metastases N (0), in LSCC in patients with lymph node metastases
N (+). Brown color corresponds to localization of CDK1 antigen, anti-
body complex visualized by peroxidase system, and developed by DAB
as a chromogen, nucleus counterstained with hematoxylin. Primary ob-
jective magnification ×10
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CDK1 is suifficient to drive the cell cycle in mammalian cells
[31] which indicates the leading role of this kinase in cell cycle
regulation. Moreover, as was shown in previous papers,
CDK1 gene phosphorylates a group of transcription factors
(TF) involved in cell cycle control and cell proliferation
[32, 33].
Nowadays, large field of cancer studies focuses on the
identification of novel, potential oncogenes or tumor suppres-
sor genes. The detailed knowledge of tumor genetic back-
ground is fundamental for establishing new diagnostic and
treatment strategies, including targeted therapy. Genetic
data have been successfully transformed into clinical
practice, for example for chronic myeloid leukemia
(CML) where the application of BCR-ABL tyrosine ki-
nase inhibitor—imatinib is widely used [34], and in
case of HER2-positive breast cancer, combination of
lapatynib and transtuzumab is applied for inhibition of
HER2 [35]. So far, for head and neck tumors, only
Cetuximab has been approved for treatment [36]. Here,
we have analyzed a potential target for an inhibition
therapy—CDK1 in larynx squamous cell carcinoma
(LSCC) and show its overexpression in this tumor.
Importantly, Goga et al. showed that the inhibtion of
CDK1 gene leads to downregulation of survivin expres-
sion and induction of MYC-dependent apoptosis [37].
Moreover, the CDK1 gene silencing with the application
of RNAi was indicated as a novel potential tool for the
therapy of malignant pleural mesothelioma [38], epithe-
lial ovarian cancer [39], and breast cancer [40, 41]. The
in-depth analysis of our microarray expression profiles
showed higher CDK1 expression in both larynx cancer
cell lines and primary tumor samples in comparison to
normal controls. This observation was further confirmed
with the application of quantitative real-time PCR tech-
nique. This is in line with previous results showed by
Lian et al. in larynx cancer tissues compared to adjacent
non-neoplastic tissues [17]. Besides, CDK1 overexpres-
sion in cancer was shown also for oral squamous cell
carcinoma [42], breast cancer [43], epithelial ovarian
cancer [39], and hepatocellular carcinoma [44].
To confirm overexpression of CDK1 on protein level, we
performed theWestern blot analysis. Our results indicated that
the expression of CDK1 protein is absent or very weak inmost
of the normal larynx tissue as compared to LSCC cell lines.
Moreover, in LSCC cell lines, the CDK1 protein was charac-
teristic for phosphorylation at threonine 161, and it was shown
that this is a feature of CDK1 activation [45]. However, the
immunohistochemical analysis of laryngeal cancer tissue sec-
tions has revealed that the CDK1 protein is present both in
cancer and non-cancer tissue samples (histopathologically
normal surgical margins of laryngeal tumors). We suppose
that these inconsistencies result from the differences of rou-
tinely used control samples. For the Western blot analysis, the
control samples consisted of commercially offered total larynx
tissue lysates and samples derived from the non-cancer dis-
ease interventions in the vicinity of the larynx, and as such,
material is free from cancerogenic process. In samples derived
from the other non-cancer samples, the trace amounts of
CDK1 protein were observed. On the other hand, the control
samples applied in immunohistochemistry (IHC) studies
were derived from surgical margins of laryngeal tumors.
The literature data indicate that such material, even if
histopathologically normal, may contain genetic alter-
ations appearing as the result of field cancerization pro-
cess [46]. This is exemplified by the fact that second
primary tumors frequently develop in patients after lar-
yngectomy. Thus, the surgery margins contain cells that
can transform into cancer. It is probable then that de-
regulation of CDK1 gene expression and the altered
protein level occurs on very early step of carcinogene-
sis. The role of CDK1 protein overexpression in surgery
margins of laryngeal cancer was noticed by Yang and
coworkers [16] who had shown its relation with the
local relapse occurrence. The CDK1 protein overexpres-
sion in OSCC was also shown in Xin Chen group, who
had shown the presence of CDK1 protein in non-cancer
epithelium in 35 % of OSCC cases and in 67.5 % of
oral cancer samples [47].
We have also analyzed the nuclear-cytoplasmic ratio
of CDK1 expression. In our study, no significant chang-
es were found in the LSCC group as compared to nor-
mal mucosa samples. Also, no differences were shown
within the LSCC samples group when the N0 group
was compared to N+ group. This is in contrast to find-
ings from colorectal tumor when it has been shown that
high nuclear/cytoplasmic ratio of CDK1 expression is
connected with poor prognosis in this type of cancer
[48].
We further seek to identify mechanisms that poten-
tially underlay the altered expression of CDK1 gene. We
searched for activated mutation by Sanger sequencing
that could possible explain CDK1 overexpression. In
this analysis, two nucleotide polymorphisms (SNP)—
rs1871446 and rs3212319 were detected. In our study,
in 25 LSCC cell lines for polymorphism rs1871446, 1
homozygous (A/A), 4 heterozygous alterations (A/G),
and 20 homozygotes (G/G) were detected. No correla-
tion of analyzed SNP with patient survival time was
observed; thus, we did not confirm any influence of
GG homozygotes on the course of laryngeal cancer.
Interestingly the second polymorphism, rs3212319 re-
sults in a deletion of cytosine in +5 position of intron
6. Of 15 affected samples, 13 were heterozygotes (C/−),
and 2 were deleted in a homozygous manner (−/−). To
verify whether this sequence variation induces changes
in CDK1 protein length, the N-terminal anti-CDK1
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antibody was used for the Western blot approached.
Lysates of seven LSCC cell lines (two heterozygotes and
two altered homozygotes) were used. The results of this anal-
ysis suggest that rs3212319 has no influence on CDK1 protein
length. Moreover, no correlations of the observed polymor-
phisms with expression level of CDK1 gene on both mRNA
and protein level in LSCC cell lines were found.
Therefore, using array-CGH, we excluded that gain of copy
number of the CDK1 gene is responsible for the transcription-
al upregulation. Further, we found no differences in the gene
promoter methylation level between in LSCC cell lines, pri-
mary tumors, and control samples. Therefore, we conclude
that lack of DNAmethylation in CDK1 promoter region com-
prises a normal condition found in healthy controls and thus
cannot be considered as the mechanism driving CDK1
overexpression.
Lastly, we hypothesized thatCDK1 overexpression may be
connected with downregulation of a microRNA that regulate
the gene. It is already known that microRNA-7 and miR-
490-3-p target CDK1 gene [49, 50]. Interestingly,
microRNA-7 is downregulated in adrenocortical carcino-
ma and transfected to the cells and leads to the inhibi-
tion of CDK1 gene. Moreover, a group of other
microRNAs was identified as potentially involved in
the regulation of CDK1 gene in laryngeal cancer. Among
them, the hsa-miR-139, hsa-miR-203, and miR-145 downreg-
ulation were observed in larynx and hypopharynx tumor
samples [51, 52]. However, our study did not confirm
these data—no changes in the expression profile of any
of these microRNAs were observed using a microarray
profiles.
Conclusion
In summary, our results show that CDK1 gene expres-
sion is recurrently elevated in LSCC. Moreover, it sug-
gests that the alterations may appear in the very early
step of carcinogenesis, as its mRNA and protein abun-
dance is observed in surgery margin and T1 tumors.
These data and the important role of CDK1 in cell
cycle regulation and control as well as the proven im-
pact of gene silencing on the tumor cell growth imply
that this gene may function as a potential oncogene.
However, the confirmation of the oncogenic character
of CDK1 gene requires further study. Our attempts to
identify the molecular mechanisms failed because we
did not observe significant changes neither in the DNA se-
quence nor in the gene copy number. Similarly, the pyrose-
quencing and miRNA expression analyses did not reveal any
differences in methylation level and miRNA expression, re-
spectively; thus these mechanisms probably do not contribute
to elevated of CDK1 expression observed in LSCC.
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